Target intelligence / Profile preview

Extracellular matrix (Dermal) (ECM)

Target
ECM
Molecular classification
Other
01

Overview

The dermal extracellular matrix (ECM) is a complex, three-dimensional network of macromolecules, including collagen, elastin, and glycosaminoglycans, that provides structural and biochemical support to skin cells (StatPearls, 2023). In the context of chronic wounds, the dermal matrix is pathologically altered, characterized by excessive degradation by matrix metalloproteinases (MMPs) and a failure to support normal cellular activities such as migration and proliferation (Schultz & Wysocki, 2009). This degradation creates a hostile microenvironment that prevents the wound from progressing through the normal stages of healing (Nunan et al., 2014). Therapeutic strategies targeting the chronic wound dermal matrix involve the use of enzymatic debriding agents like collagenase to remove damaged tissue, growth factors like becaplermin to stimulate repair, or acellular dermal matrices to provide a fresh scaffold for tissue regeneration (FDA, 1997; Nunan et al., 2014). By restoring the integrity and function of the matrix, these interventions aim to facilitate the recruitment of fibroblasts and keratinocytes, ultimately leading to successful wound closure and tissue remodeling.

Other names
Dermal extracellular matrixWound bed matrixDermal scaffoldChronic wound environmentAcellular dermal matrix
02

Mechanism of action

Providing a structural scaffold for cellular migration and proliferation, sequestering and protecting endogenous growth factors from proteolytic degradation, and modulating the inflammatory microenvironment to promote the transition from the inflammatory to the proliferative phase of healing.

03

Biological functions

Cell adhesionSignal transductionStructural supportGrowth factor sequestrationCell migrationCell proliferation
04

Disease associations

Chronic woundDiabetic foot ulcerVenous leg ulcerPressure ulcerInfection
05

Safety considerations

Risk of hypersensitivity or allergic reactions to animal-derived matrix componentsPotential for promoting localized infection if the wound is not properly debridedTheoretical risk of malignancy with prolonged use of certain growth factors like becaplerminBio-incompatibility
06

Interacting drugs

Becaplermin

4 more in the full profile.

07

Biomarkers

Matrix metalloproteinase-9 (MMP-9)Tissue inhibitor of metalloproteinases-1 (TIMP-1)HydroxyprolineMMP/TIMP ratio

Beyond the preview

Go deeper on Extracellular matrix (Dermal) (ECM).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Extracellular matrix (Dermal) (ECM).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call